Urate-Lowering Therapy on Chronic Kidney Disease and Gout Patients

Recent Findings
Recent studies indicate that lowering serum urate levels to below 6 mg/dL with urate-lowering therapy (ULT) can reduce the risk of kidney disease progression in patients with gout and stage III chronic kidney disease (CKD).

---

Significance of Urate-Lowering Therapy

Patients with both CKD and gout are at a higher risk of accelerated kidney function decline when urate levels are elevated. The study demonstrated that patients who achieved serum urate levels below 6 mg/dL experienced a significantly lower risk of severe or end-stage kidney disease over five years compared to those who did not.

---

Study Overview

• • Participants:
    • 14,972 patients with stage III CKD and gout (mean age: 73.1 years, 37.7% female).
    • Baseline serum urate level: 8.9 mg/dL.
    • Initiated ULT using allopurinol or febuxostat.
  • Methodology:
    • Patients were divided into two groups: those who achieved serum urate levels below 6 mg/dL and those who did not.
    • Compared the risk of severe or end-stage kidney disease over five years.
  • Results:
    • The risk of kidney disease progression was significantly lower in the group achieving target urate levels (10.32%) compared to those who did not (12.73%).
    • Adjusted hazard ratio (HR): 0.89 (95% confidence interval: 0.80-0.98).

---

Clinical Implications

• Lowering serum urate levels may slow the progression of kidney disease, improving patients’ quality of life.
• Optimizing the use of ULT and improving patient adherence to treatment is critical for effective management.

---

Limitations of the Study

• As an observational study, residual confounding variables might still exist.
• Patients who achieved the target urate levels might have received better healthcare or adhered to treatments more diligently.
• Findings may have limited generalizability.

---

Conclusion

Lowering serum urate levels to below 6 mg/dL is a safe and effective strategy to slow the progression of kidney disease in patients with stage III CKD and gout.

---

Tips for Managing Health

Effectiveness of Treatment

• Achieving a serum urate level below 6 mg/dL can significantly slow the progression of CKD and gout.
• ULT is safe and beneficial for kidney health.

Health Management Advice

1. Consistency in Treatment: Regularly follow prescribed ULT and dietary plans to maintain urate levels.
2. Customized Care Plans: Consult with a nephrologist or dietitian to create a personalized treatment and dietary strategy.

---

Does Eating Processed Foods Cause Breast Cancer?

Harvard Health Publishing